CN104703655A - 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 - Google Patents
具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 Download PDFInfo
- Publication number
- CN104703655A CN104703655A CN201380053015.8A CN201380053015A CN104703655A CN 104703655 A CN104703655 A CN 104703655A CN 201380053015 A CN201380053015 A CN 201380053015A CN 104703655 A CN104703655 A CN 104703655A
- Authority
- CN
- China
- Prior art keywords
- base
- pharmaceutically acceptable
- solvate
- acceptable salt
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124647 MEK inhibitor Drugs 0.000 title description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title description 6
- 230000001093 anti-cancer Effects 0.000 title description 4
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 77
- 239000012453 solvate Substances 0.000 claims abstract description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 29
- -1 iodo-phenyl amino Chemical group 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 229960005206 pyrazinamide Drugs 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims description 12
- 210000000481 breast Anatomy 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 210000003800 pharynx Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 210000003238 esophagus Anatomy 0.000 claims description 5
- 210000000867 larynx Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 230000000086 blastomogenic effect Effects 0.000 claims description 3
- 210000000621 bronchi Anatomy 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 abstract 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 60
- 239000002585 base Substances 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 49
- 239000003513 alkali Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000825 pharmaceutical preparation Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 210000003739 neck Anatomy 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000009311 VIPoma Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 229940043237 diethanolamine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229940012017 ethylenediamine Drugs 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-NRXMZTRTSA-N (2r,3r,4r,5s)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-NRXMZTRTSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 238000011786 NMRI nude mouse Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000001942 asparaginyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 229960002536 benzathine benzylpenicillin Drugs 0.000 description 1
- WWIWLTSSHDKOKO-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 WWIWLTSSHDKOKO-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
一种药用组合物，其包含3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-(S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物。
Description
发明领域
本发明涉及用于癌症疾病的药用组合物，其包含具有抗-癌活性的化合物，即与MEK抑制剂，即N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合的3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物。
发明背景
本发明的目的在于发现新的具有有价值性质的药用组合物，特别是那些可用来制备药物的组合物。
此外，本发明的目的是用于预防和治疗恶性肿瘤包括，但不限于，实体瘤癌症、淋巴或血液系统的癌症的新组合物。
已经发现，依据本发明的药用组合物及其药学上可接受的盐和/或溶剂合物具有非常有价值的药用性质，同时是良好耐受的。
靶向疗法选择性地抑制肿瘤中的特定靶标。通过将这些靶向疗法与护理标准(SoC)结合，可以改善SoC的活动。已经发现，通过将3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合，改进了抗癌化合物在异种移植物中的活性。
与单一疗法比较，在NSCLC (非小细胞肺癌)异种移植模型中的功效得到提高。观察到联合组的功效增强而没有增加毒性。
现有技术
在WO 2009/006959 A1中已经描述了3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈。
在WO 2009/007074 A1中已经描述了3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物。
在WO 2012/078832 A1中描述了MEK抑制剂N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺与PI3K抑制剂的组合。
发明简述
本发明涉及一种组合物，其包含3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物。
此外，本发明涉及一种组合物，其包含3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物。
此外，本发明涉及3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物的组合物，其用于治疗选自以下的疾病：头、颈、眼、口、喉咙、食管、支气管、喉、咽、胸、骨、肺、结肠、直肠、胃、前列腺、膀胱、子宫、子宫颈、乳房、卵巢、睾丸或其它生殖器官、皮肤、甲状腺、血、淋巴结、肾、肝、胰腺、脑、中枢神经系统、实体瘤和血生肿瘤的癌症。
此外，本发明涉及3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物在制备用于治疗癌症的药物中的用途，所述癌症选自结肠直肠、肺、乳房、肾和胶质母细胞瘤，其中所述药物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合使用。
此外，本发明涉及3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物在制备用于治疗癌症的药物中的用途，所述癌症选自结肠直肠、肺、乳房、肾和胶质母细胞瘤，其中所述药物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合使用。
此外，本发明涉及3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物在制备用于治疗癌症的药物中的用途，所述癌症选自小细胞肺癌(SCLC)、非小细胞肺癌(NSCLC)、头和颈的鳞状细胞癌(SCCHN)，其中所述药物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合使用。
此外，本发明涉及如上所述的用途，其中3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物或3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物以每周250 mg-12500 mg的量，优选以每周800 mg-8000 mg的量，特别优选以每周500 mg-2000 mg的量给予患者。
依据本发明，治疗活性组合物也可通过药剂盒提供，所述药剂盒包含含有在单一包装中或在分开的容器中的3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物的包装。
采用这些组合的疗法可任选地包括用放射进一步治疗。本发明还涉及一种新的疗法形式，其包括在放射疗法之前开始给予3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物。
在包括在放射疗法之前开始给予3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物的这种新的疗法形式中，优选的特点是，在给予其它癌症共治疗剂(cotherapeutic agent)之前和/或期间，优选至少在治疗方案的重要部分期间，给予3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物。在本上下文中，依据本发明，辐射或放射治疗，优选要理解为一种癌症共治疗剂。
本发明还涉及这些化合物的任选的活性形式(立体异构体)、对映体、外消旋体、非对映体和水合物和溶剂合物。
本发明还涉及所述化合物的盐的溶剂合物，例如盐酸盐的一水合物或二水合物。
术语化合物的溶剂合物用以指内收惰性溶剂分子到化合物上，其由于它们的相互吸引力而形成。溶剂合物例如为单或二水合物或醇化物。
表述“有效量”表示在组织、系统、动物或人类中引起例如由研究人员或医师所探求或希望的生物学或医学反应的药物或药学活性成分的量。
另外，表述“治疗有效量”表示与没有接收该量的相应受试者相比较具有以下结果的量：
治疗改善、痊愈、预防或消除疾病、综合征、病况、症状、病症或副作用或者还有降低疾病、症状或病症的进展。
表述“治疗有效量”还涵盖有效增加正常生理功能的量。
药用盐和其它形式
根据本发明的所述化合物可以其最终非盐形式使用。另一方面，本发明还涵盖以其药学上可接受的盐的形式的这些化合物的用途，所述药学上可接受的盐可通过本领域已知的方法得自各种有机和无机的酸和碱。3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺的药学上可接受的盐形式大部分通过常规方法制备。
如果化合物含有羧基，则其合适盐中的一种可通过使所述化合物与合适的碱反应得到相应的碱加成盐来形成。所述碱例如为碱金属氢氧化物，包括氢氧化钾、氢氧化钠和氢氧化锂；碱土金属氢氧化物，诸如氢氧化钡和氢氧化钙；碱金属醇盐，例如乙醇钾和丙醇钠；和各种有机碱，诸如哌啶、二乙醇胺和N-甲基谷氨酰胺。同样包括所述化合物的铝盐。在某些化合物的情况下，酸加成盐可通过用以下药学上可接受的有机和无机酸处理这些化合物来形成：例如卤化氢，诸如氯化氢、溴化氢或碘化氢；其它无机酸及其相应盐，诸如硫酸盐、硝酸盐或磷酸盐等；和烷基和单芳基磺酸盐，诸如乙烷磺酸盐、甲苯磺酸盐和苯磺酸盐；及其它有机酸及其相应盐，诸如乙酸盐、三氟乙酸盐、酒石酸盐、马来酸盐、琥珀酸盐、柠檬酸盐、苯甲酸盐、水杨酸盐、抗坏血酸盐等。因此，所述化合物的药学上可接受的酸加成盐包括以下：乙酸盐、已二酸盐、海藻酸盐、精氨酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐(benzenesulfonate)(苯磺酸盐(besylate))、硫酸氢盐、亚硫酸氢盐、溴化物、丁酸盐、樟脑酸盐、樟脑磺酸盐、辛酸盐、氯化物、氯苯甲酸盐、柠檬酸盐、环戊烷丙酸盐、二葡萄糖酸盐、二氢磷酸盐、二硝基苯甲酸盐、十二烷基硫酸盐、乙烷磺酸盐、富马酸盐、半乳糖二酸盐(由粘酸得到)、半乳糖醛酸盐、葡庚糖酸盐、葡糖酸盐、谷氨酸盐、甘油磷酸盐、半琥珀酸盐、半硫酸盐、庚酸盐、己酸盐、马尿酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、2-羟基乙烷磺酸盐、碘化物、羟乙基磺酸盐、异丁酸盐、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、丙二酸盐、扁桃酸盐、偏磷酸盐、甲烷磺酸盐、甲基苯甲酸盐、单氢磷酸盐、2-萘磺酸盐、烟酸盐、硝酸盐、草酸盐、油酸盐、棕榈酸盐(palmoate)、果胶酸盐、过硫酸盐、苯乙酸盐、3-苯基丙酸盐、磷酸盐、膦酸盐、邻苯二甲酸盐，但这不代表限制。
另外，根据本发明的化合物的碱式盐包括铝、铵、钙、铜、铁(III)、铁(II)、锂、镁、锰(III)、锰(II)、钾、钠及锌盐，但这并非意欲代表限制。在上述盐之中，优选铵、碱金属钠和钾盐及碱土金属钙和镁盐。得自药学上可接受的有机无毒碱的化合物的盐包括以下的盐：伯、仲和叔胺；被取代的胺，还包括天然存在的被取代的胺；环胺；和碱离子交换树脂，例如精氨酸、甜菜碱、咖啡因、氯普鲁卡因、胆碱、N,N'-二苄基乙二胺(苄星青霉素)、二环己胺、二乙醇胺、二乙胺、2-二乙基氨基乙醇、2-二甲基氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、还原葡糖胺、葡糖胺、组氨酸、哈胺(hydrabamine)、异丙胺、利多卡因(lidocaine)、赖氨酸、葡甲胺、N-甲基-D-葡糖胺、吗啉、哌嗪、哌啶、聚胺树脂、普鲁卡因、嘌呤、可可碱、三乙醇胺、三乙胺、三甲胺、三丙胺和三(羟甲基)甲胺(缓血酸胺)，但这并非意欲代表限制。
含有碱性含氮基团的本发明化合物可使用例如以下试剂季胺化：(C1-C4)烷基卤化物，例如甲基、乙基、异丙基和叔丁基氯化物、溴化物和碘化物；硫酸二(C1-C4)烷基酯，例如硫酸二甲酯、硫酸二乙酯和硫酸二戊酯；(C10-C18)烷基卤化物，例如癸基、十二烷基、月桂基、肉豆寇基和十八烷基氯化物、溴化物和碘化物；和芳基(C1-C4)烷基卤化物，例如苄基氯和苯乙基溴。根据本发明的水溶性和油溶性化合物两者都可使用这样的盐制备。
优选的上述药学上的盐包括乙酸盐、三氟乙酸盐、苯磺酸盐、柠檬酸盐、富马酸盐、葡糖酸盐、半琥珀酸盐、马尿酸盐、盐酸盐、氢溴酸盐、羟乙基磺酸盐、扁桃酸盐、葡甲胺、硝酸盐、油酸盐、膦酸盐、新戊酸盐、磷酸钠、硬脂酸盐、硫酸盐、磺基水杨酸盐、酒石酸盐、硫代苹果酸盐、甲苯磺酸盐和缓血酸胺，但这并非意欲代表限制。
特别优选盐酸盐、二盐酸盐、氢溴酸盐、马来酸盐、甲磺酸盐、磷酸盐、硫酸盐和琥珀酸盐。
所述碱性化合物的酸加成盐通过使游离碱形式与足够量的所需酸接触，促使以常规形式形成所述盐来制备。所述游离碱可通过使所述盐形式与碱接触并以常规方式分离所述游离碱而再生。所述游离碱形式在某方面关于某些物理性质如在极性溶剂中的溶解性而与其相应盐形式不同；然而，对于本发明的目的，所述盐在其它方面与其相应游离碱形式一致。
如所提到的，所述化合物的药学上可接受的碱加成盐用金属或胺如碱金属和碱土金属或有机胺形成。优选的金属有钠、钾、镁和钙。优选的有机胺有N,N’-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺、N-甲基-D-葡糖胺和普鲁卡因。
根据本发明的酸性化合物的碱加成盐通过使所述游离酸形式与足够量的所需要的碱接触，促使以常规方式形成所述盐来制备。所述游离酸可通过使所述盐形式与酸接触并以常规方式分离所述游离酸而再生。所述游离酸形式在某方面关于某些物理性质如在极性溶剂中的溶解性而与其相应盐形式不同；然而，对于本发明的目的，所述盐在其它方面与其相应游离酸形式一致。
如果根据本发明的化合物含有多于一个能够形成该类型的药学上可接受的盐的基团，本发明则还涵盖多重盐。典型的多重盐形式例如包括酒石酸氢盐、二乙酸盐、富马酸氢盐、二葡甲胺、磷酸氢盐、二钠和三盐酸盐，但这并非意欲代表限制。
关于上文所述，可见在本上下文中的表述“药学上可接受的盐”用以指活性成分，其包含以其盐中的一种的形式的化合物，特别是如果与活性成分的游离形式或先前使用的活性成分的任何其它盐形式相比较，该盐形式赋予活性成分改善的药代动力学性质。所述活性成分的药学上可接受的盐形式还可首次提供给该活性成分先前没有的所要的药代动力学性质，且关于其在体内的治疗功效，甚至可以对该活性成分的药效学具有有利的影响。
本发明另外涉及药物，所述药物包含至少一种化合物和/或其药学上可接受的盐、溶剂合物、互变异构体和立体异构体，包括其以所有比率的混合物，及任选的赋形剂和/或助剂。
药物制剂可以包含预定量的活性成分/剂量单位的剂量单位形式施用。所述单位可根据所治疗的病况、施用方法及患者的年龄、体重和病况而包含例如0.5mg-1g、优选1mg-700mg、特别优选5mg-100mg的本发明化合物，或者药物制剂可以包含预定量的活性成分/剂量单位的剂量单位形式施用。优选的剂量单位制剂为包含如上指出的日剂量或份剂量或其相应分数的活性成分的那些。另外，该类型的药物制剂可使用在制药领域中通常已知的方法制备。
药物制剂可适合经由任何需要的合适方法，例如经口(包括颊或舌下)、直肠、鼻、局部(包括颊、舌下或经皮)、阴道或肠胃外(包括皮下、肌肉内、静脉内或皮内)方法施用。所述制剂可使用制药领域中已知的所有方法通过例如将活性成分与赋形剂或助剂组合来制备。
适合口服的药物制剂可作为独立单位如胶囊或片剂；粉剂或颗粒剂；在水性或非水性液体中的溶液剂或混悬剂；可食用泡沫或泡沫食品；或水包油液体乳剂或油包水液体乳剂来施用。
因此，例如，在以片剂或胶囊形式口服的情况下，可将活性成分组分与经口、无毒且药学上可接受的惰性赋形剂如乙醇、甘油、水等组合。粉剂通过将化合物粉碎成合适的小尺寸并将其与以类似方式粉碎的药用赋形剂如可食用的碳水化合物如淀粉或甘露糖醇混合来制备。同样可存在矫味剂、防腐剂、分散剂和染料。
胶囊通过制备如上所述的粉末混合物并用其填充成型的明胶壳来生成。在填充操作之前可将诸如以固体形式的高度分散的硅酸、滑石粉、硬脂酸镁、硬脂酸钙或聚乙二醇等助流剂和润滑剂加到所述粉末混合物中。同样可加入诸如琼脂、碳酸钙或碳酸钠等崩解剂或增溶剂以改善服用胶囊之后药物的利用度。
另外，如果需要或必需，则同样可将合适的粘合剂、润滑剂和崩解剂以及染料掺入所述混合物中。合适的粘合剂包括淀粉、明胶、天然糖如葡萄糖或β-乳糖、由玉米制造的甜味剂、天然和合成橡胶如阿拉伯胶、黄蓍胶或海藻酸钠、羧甲基纤维素、聚乙二醇、蜡等。在这些剂型中使用的润滑剂包括油酸钠、硬脂酸钠、硬脂酸镁、苯甲酸钠、乙酸钠、氯化钠等。所述崩解剂包括(而不受此限制)淀粉、甲基纤维素、琼脂、膨润土、黄原胶等。所述片剂通过例如制备粉末混合物、造粒或压干所述混合物、加入润滑剂和崩解剂并压制全部混合物以给出片剂来配制。粉末混合物通过混合以合适方式粉碎的化合物与如上所述的稀释剂或基质和任选粘合剂如羧甲基纤维素、海藻酸盐、明胶或聚乙烯吡咯烷酮；溶解延缓剂如石蜡；吸收加速剂如季盐；和/或吸收剂如膨润土、高岭土或磷酸二钙来制备。所述粉末混合物可通过用粘合剂如糖浆、淀粉糊、阿卡迪亚胶浆或纤维素或聚合物材料的溶液将其润湿并挤压穿过筛网来造粒。作为造粒的替代，可使所述粉末混合物穿过制片机，给出不均匀形状的结块，将其破碎以形成颗粒剂。所述颗粒剂可通过加入硬脂酸、硬脂酸盐、滑石粉或矿物油润滑以免粘住片剂铸模模具。随后将润滑的混合物压制以给出片剂。根据本发明的化合物还可与自由流动的惰性赋形剂组合且随后直接压制给出片剂而不进行造粒或压干步骤。可存在由虫胶封闭层、糖或聚合物材料的层和蜡的光泽层组成的透明或不透明的保护层。可将染料加到这些涂层中以能够区分开不同的剂量单位。
口服液体如溶液、糖浆和酏剂可以剂量单位形式制备，以使得给定的量包含预定量的所述化合物。糖浆可通过将所述混合物溶解于具有合适矫味剂的水溶液中来制备，而酏剂使用无毒醇媒剂制备。混悬剂可通过将所述化合物分散在无毒媒剂中来配制。同样可加入增溶剂和乳化剂，诸如乙氧化异十八醇和聚氧乙烯山梨糖醇醚；防腐剂；调味添加剂，诸如薄荷油；或天然甜味剂或糖精；或其他人工甜味剂等。
如果需要，可将用于口服的剂量单位制剂封装在微囊中。所述制剂还可以延迟释放或阻释的方式来制备，例如通过将微粒材料涂布或包埋在聚合物、蜡等中。
所述化合物及其盐、溶剂合物、互变异构体和立体异构体还可以脂质体传送系统如小单层囊泡、大单层囊泡和多层囊泡的形式施用。脂质体可由各种磷脂诸如胆固醇、十八胺或磷脂酰胆碱形成。
所述化合物及其盐、溶剂合物、互变异构体和立体异构体还可使用单克隆抗体作为化合物分子与其偶联的单独的载体来递送。所述化合物也可偶联到作为靶向药物载体的可溶性聚合物。所述聚合物可包括聚乙烯吡咯烷酮、吡喃共聚物、聚羟基丙基甲基丙烯酰胺基苯酚、聚羟基乙基天冬酰胺基苯酚或被棕榈酰基取代的聚环氧乙烷聚赖氨酸。所述化合物可另外偶联到一类可生物降解的聚合物，所述可生物降解的聚合物适合用于实现药物的受控释放，例如聚乳酸、聚ε-己内酯、聚羟基丁酸、聚原酸酯、聚缩醛、聚二羟基吡喃、聚氰基丙烯酸酯和水凝胶的交联或两亲的嵌段共聚物。
适合经皮施用的药物制剂可作为独立膏剂施用以便与接受者的表皮扩展地紧密接触。因此，例如，活性成分可通过离子电渗从膏剂中递送，如在Pharmaceutical Research, 3(6), 318 (1986)的一般术语中所述。
可将适合局部施用的药物化合物配制为软膏、乳膏、混悬剂、洗液、粉剂、溶液剂、糊剂、凝胶剂、喷剂、气溶胶或油剂。
为了治疗眼睛或其它外部组织如口和皮肤，所述制剂优选作为局部软膏或乳膏施用。在产生软膏的制剂的情况下，活性成分可与石蜡或水混溶的膏基一起使用。或者，活性成分可用水包油膏基或油包水基质一起配制以产生乳膏。
适合局部施用到眼睛的药物制剂包括滴眼剂，其中活性成分溶解或悬浮在合适载体、特别是水性溶剂中。
适合在口中局部施用的药物制剂包括锭剂、软锭剂和漱口剂。
适合直肠施用的药物制剂可以栓剂或灌肠剂的形式施用。
其中载体物质为固体的适合经鼻施用的药物制剂包括具有例如在20-500微米范围内的粒度的粗粉剂，其以采用嗅剂的方式，即通过从保持靠近鼻的含有粉剂的容器经鼻道迅速吸入来施用。用于作为具有液体作为载体物质的鼻喷剂或滴鼻剂施用的合适制剂包括在水或油中的活性成分溶液。
适合通过吸入施用的药物制剂包括细微粒粉尘或烟雾，其可通过各种类型的具有气溶胶的加压分配器、喷雾器或吹入器产生。
适合阴道施用的药物制剂可作为子宫托、棉塞、乳膏、凝胶剂、糊剂、泡沫或喷雾制剂施用。
适合肠胃外施用的药物制剂包括水性和非水性无菌注射液，其包含抗氧化剂、缓冲剂、抑菌剂和溶质，借助于所述无菌注射液使所述制剂与欲治疗的接受者的血液等渗；和水性和非水性无菌混悬液，其可包含悬浮介质和增稠剂。所述制剂可在单剂量或多剂量容器如密封安瓿和小瓶中施用并以冷冻干燥(冻干)状态储存，以使得仅需要紧接在使用之前加入无菌载液，例如用于注射目的的水。根据该配方制备的注射溶液和混悬液可由无菌粉末、颗粒剂和片剂制备。
不用说，关于特定制剂类型，除了以上特别提到的成分之外，所述制剂还可包含本领域中常用的其他试剂；因此，例如，适合口服的制剂可包含矫味剂。
化合物的治疗有效量取决于许多因素，例如包括动物的年龄和体重、需要治疗的精确病况及其严重性、制剂的性质和施用方法，且其最终由治疗医师或兽医确定。然而，根据本发明的化合物的有效量通常在0.1-100 mg/kg接受者(哺乳动物)体重/日的范围内且特别典型地在1-10 mg/kg体重/日的范围内。因此，对于体重为70 kg的成年哺乳动物每日的实际量通常为70-700 mg，其中该量可以每日单一剂量或通常以每日一系列多份剂量(诸如2、3、4、5或6份)施用，以使得日总剂量相同。其盐、溶剂合物、互变异构体及立体异构体的有效量可确定为本发明的化合物的有效量本身的分数。可以假定类似的剂量适合用于治疗上述其他病况。
该类型的组合疗法可借助于同时、连续或单独分配该治疗的单独组分来实现。该类型的组合茶品采用根据本发明的化合物。
本文定义的抗-癌治疗可作为单一疗法施用或除了本发明的组合物外，还可包括常规手术或放射疗法。
本文使用的“治疗”是指完全或部分地减轻与疾病或病症相关的症状，或减慢或中止那些症状的进一步进展或恶化，或防止或预防处于发展该疾病或病症的危险之中的受试者的疾病或病症。
结合化合物的术语“有效量”可以指能够完全或部分地减轻与疾病或病症相关的症状，或减慢或中止那些症状的进一步进展或恶化，或防止或预防具有本文公开的疾病或处于发展本文公开的疾病的危险之中的受试者的疾病或病症的量，所述疾病例如癌症。
术语“治疗有效的”或“治疗有效量”指有效治疗哺乳动物的疾病或病症的药物的量。在癌症的情况下，药物的治疗有效量可减少癌细胞的数量；减小肿瘤大小；抑制(即，延缓至某种程度和最好是停止)癌细胞浸润进入周围器官；抑制(即，延缓至某种程度和最好是停止)肿瘤转移；抑制(至某种程度)肿瘤生长；和/或将癌症相关的一种或多种症状缓解至某种程度。在药物可防止生长和/或杀灭已存在的癌细胞的程度上，其可以是抑制细胞生长的和/或细胞毒性的。对于癌症治疗，效果可例如通过评估至疾病进展的时间(TTP)和/或确定响应率(RR)来测量。
优选地，厄洛替尼(erlotinib)、西妥昔单抗、阿柏西普(aflibercept)、贝伐单抗一周施用一次，优选为静脉内输注。优选初始剂量为100-1000 mg/m2体表面积，特别优选200-600 mg/m2体表面积。后续剂量为50-600 mg/m2体表面积，特别优选100-400 mg/m2体表面积。
用途
本发明化合物适合作为对于哺乳动物、特别是对于人类而言在治疗免疫调节和应激反应激酶诱发的疾病中的药物活性成分。这些疾病包括恶性肿瘤，包括，但不限于，实体瘤癌症、淋巴或血液系统的癌症、瘤细胞增殖、促使实体瘤生长的病理性新血管形成(或血管生成)、神经退行性疾病(阿尔茨海默氏病、脱髓鞘核心疾病多发性硬化症等)、免疫相关病症如关节炎、银屑病、狼疮，或其它自身免疫性疾病以及慢性感染。
本发明包括所述化合物和/或其生理学上可接受的盐和溶剂合物在制备用于治疗或预防癌症的药物中的用途。为治疗的优选癌起源于以下一组癌症：脑癌、泌尿生殖道癌、淋巴系统癌、胃癌、喉癌和肺癌。另一组优选形式的癌症为单核细胞白血病、肺腺癌、小细胞肺癌、胰腺癌、胶质母细胞瘤、黑素瘤和乳腺癌。另一组优选形式的癌症包括，但不限于，子宫颈癌、神经母细胞瘤、睾丸癌、巨球蛋白血症和肉瘤。
本发明特别涉及化合物及其药学上可接受的盐、溶剂合物、互变异构体和立体异构体，包括其以所有比率的混合物，其用于治疗恶性肿瘤(实体瘤癌症、淋巴或血液系统的癌症等)、神经退行性疾病、免疫相关病症如关节炎、银屑病、狼疮、多发性硬化或其它自身免疫性疾病以及慢性感染。
特别优选的是治疗其中疾病是恶性肿瘤的疾病中的用途。
恶性肿瘤优选选自肺、鳞状上皮、膀胱、胃、肾、头和颈、食管、子宫颈、甲状腺、肠、肝、脑、前列腺、泌尿生殖道、淋巴系统、胃和/或喉的癌症。
恶性肿瘤还优选选自肺腺癌、小细胞肺癌、胰腺癌、胶质母细胞瘤、结肠癌和乳腺癌。
进一步给出的优选是用于治疗血和免疫系统的恶性肿瘤，优选用于治疗选自急性髓细胞性白血病、慢性髓细胞性白血病、急性淋巴性白血病和/或慢性淋巴性白血病的肿瘤中的用途。
化合物可用于治疗或预防的代表性癌症包括，但不限于头、颈、眼、口、喉咙、食管、支气管、喉、咽、胸、骨、肺、结肠、直肠、胃、前列腺、膀胱、子宫、子宫颈、乳房、卵巢、睾丸或其它生殖器官、皮肤、甲状腺、血、淋巴结、肾、肝、胰腺、脑、中枢神经系统、实体瘤和血生肿瘤的癌症。
此外，本发明特别涉及用于治疗和/或预防癌症的化合物，其中要治疗的癌症是实体瘤或血和免疫系统的癌症。
此外，本发明特别涉及用于治疗和/或预防癌症的化合物，其中肿瘤源于急性髓细胞性白血病、慢性髓细胞性白血病、急性淋巴性白血病和/或慢性淋巴性白血病。
此外，本发明特别涉及用于治疗和/或预防癌症的化合物，其中实体瘤源自上皮细胞、膀胱、胃、肾、头和颈、食管、子宫颈、甲状腺、肠、肝、脑、前列腺、泌尿生殖道、淋巴系统、胃、喉、骨(包括软骨肉瘤和尤文氏肉瘤)、生殖细胞(包括胚胎组织肿瘤)和/或肺的肿瘤，选自单核细胞白血病、肺腺癌、小细胞肺癌、胰腺癌、胶质母细胞瘤、纤维神经瘤、血管肉瘤、乳腺癌和/或恶性黑素瘤。
所公开的化合物可与包括抗癌剂的其它已知治疗剂组合施用。如在此使用的，术语“抗癌剂”涉及为治疗癌症的目的施用到具有癌症的患者的任何药剂。
在人KP-4胰腺瘤模型中与MEK抑制剂N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺的组合：
方法：对雌性BalB/c裸鼠(6-8周龄)皮下注射人KP-4胰腺瘤细胞并在产生肿瘤后将其分配到各治疗组(一组10只动物)。对各组口服3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物(100 mg/kg)或N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺(50 mg/kg)，在单一疗法或组合治疗中持续给药5天和停药2天。在治疗结束后计算T/C值并观察肿瘤再生长。统计分析用单因素方差分析(one way ANOVA)进行。结果：3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺显示出抗-肿瘤活性，其T/C值分别为35%和42%。两种药物的组合导致抗-肿瘤活性的显著增加，其T/C为14% (P<0.05)。所有治疗都是良好耐受的。
在10个患者来源的胰腺瘤模型中，与MEK抑制剂N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺的组合：
方法：雌性NMRI裸鼠(6-8周龄)皮下植入患者来源的胰腺瘤片段。在产生肿瘤后将动物分配到各治疗组(一组10只动物)。对各组口服3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物(100 mg/kg)或N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺(100 mg/kg, MTD)，在单一疗法或组合治疗中持续给药5天和停药2天。在治疗结束后计算T/C值并观察肿瘤再生长。统计分析已用单因素方差分析(one way ANOVA)进行。结果：3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物在2/10模型中显示出抗-肿瘤活性，其T/C值为43%和50%，而N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺在所有10个模型中显示出抗-肿瘤活性(T/C值< 55%)。两种药物的组合在所有模型中显示出抗-肿瘤活性的增加，其中3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物单一疗法对比组合疗法在10/10个模型中是有统计学意义的(P<0.01)和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺单一疗法对比组合在2/10个模型中是有统计学意义的(P<0.05)。所有治疗都是良好耐受的。
Claims (7)
1. 一种组合物，其包含3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物。
2. 一种组合物，其包含3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物。
3. 依据权利要求1或2的组合物，其还包含药学上可接受的赋形剂和/或助剂。
4. 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物和N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物的组合物，其用于治疗选自以下的疾病：头、颈、眼、口、喉咙、食管、支气管、喉、咽、胸、骨、肺、结肠、直肠、胃、前列腺、膀胱、子宫、子宫颈、乳房、卵巢、睾丸或其它生殖器官、皮肤、甲状腺、血、淋巴结、肾、肝、胰腺、脑、中枢神经系统、实体瘤和血生肿瘤的癌症。
5. 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物在制备用于治疗癌症的药物中的用途，所述癌症选自结肠直肠、肺、乳房、肾和胶质母细胞瘤，其中所述药物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合使用。
6. 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物在制备用于治疗癌症的药物中的用途，所述癌症选自结肠直肠、肺、乳房、肾和胶质母细胞瘤，其中所述药物与N-((S)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺或其药学上可接受的盐和/或溶剂合物组合使用。
7. 权利要求5或6的用途，其中3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈或其药学上可接受的盐和/或溶剂合物或3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐水合物以每周250 mg-12500 mg的量给予患者。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007039 | 2012-10-11 | ||
| EP12007039.6 | 2012-10-11 | ||
| PCT/EP2013/002747 WO2014056566A1 (en) | 2012-10-11 | 2013-09-13 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104703655A true CN104703655A (zh) | 2015-06-10 |
Family
ID=47048932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380053015.8A Pending CN104703655A (zh) | 2012-10-11 | 2013-09-13 | 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150297594A1 (zh) |
| EP (1) | EP2906294B1 (zh) |
| JP (1) | JP2015536910A (zh) |
| KR (1) | KR102157501B1 (zh) |
| CN (1) | CN104703655A (zh) |
| AR (1) | AR092991A1 (zh) |
| AU (1) | AU2013329865B2 (zh) |
| BR (1) | BR112015007870B1 (zh) |
| CA (1) | CA2887628C (zh) |
| ES (1) | ES2679372T3 (zh) |
| HK (1) | HK1211255A1 (zh) |
| IL (1) | IL238061B (zh) |
| MX (1) | MX359110B (zh) |
| RU (1) | RU2684407C2 (zh) |
| SG (1) | SG11201502628SA (zh) |
| WO (1) | WO2014056566A1 (zh) |
| ZA (1) | ZA201503186B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170090498A (ko) * | 2014-12-11 | 2017-08-07 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합 |
| WO2016091346A1 (en) | 2014-12-12 | 2016-06-16 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor |
| HUE051734T2 (hu) * | 2016-10-27 | 2021-03-29 | Fujian Cosunter Pharmaceutical Co Ltd | Piridon-vegyület, mint C-Met inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687857A (zh) * | 2007-07-12 | 2010-03-31 | 默克专利有限公司 | 嘧啶基哒嗪酮衍生物 |
| WO2012078832A1 (en) * | 2010-12-09 | 2012-06-14 | Sanofi | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
-
2013
- 2013-09-13 WO PCT/EP2013/002747 patent/WO2014056566A1/en active Application Filing
- 2013-09-13 AU AU2013329865A patent/AU2013329865B2/en active Active
- 2013-09-13 KR KR1020157012085A patent/KR102157501B1/ko active IP Right Grant
- 2013-09-13 US US14/434,926 patent/US20150297594A1/en not_active Abandoned
- 2013-09-13 MX MX2015004428A patent/MX359110B/es active IP Right Grant
- 2013-09-13 RU RU2015117550A patent/RU2684407C2/ru active
- 2013-09-13 CN CN201380053015.8A patent/CN104703655A/zh active Pending
- 2013-09-13 BR BR112015007870-2A patent/BR112015007870B1/pt not_active IP Right Cessation
- 2013-09-13 ES ES13762992.9T patent/ES2679372T3/es active Active
- 2013-09-13 CA CA2887628A patent/CA2887628C/en active Active
- 2013-09-13 EP EP13762992.9A patent/EP2906294B1/en active Active
- 2013-09-13 SG SG11201502628SA patent/SG11201502628SA/en unknown
- 2013-09-13 JP JP2015536004A patent/JP2015536910A/ja active Pending
- 2013-10-11 AR ARP130103703A patent/AR092991A1/es unknown
-
2015
- 2015-03-31 IL IL23806115A patent/IL238061B/en active IP Right Grant
- 2015-05-08 ZA ZA2015/03186A patent/ZA201503186B/en unknown
- 2015-12-07 HK HK15112009.7A patent/HK1211255A1/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687857A (zh) * | 2007-07-12 | 2010-03-31 | 默克专利有限公司 | 嘧啶基哒嗪酮衍生物 |
| WO2012078832A1 (en) * | 2010-12-09 | 2012-06-14 | Sanofi | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014056566A1 (en) | 2014-04-17 |
| BR112015007870B1 (pt) | 2021-12-07 |
| AU2013329865A1 (en) | 2015-05-21 |
| KR20150067343A (ko) | 2015-06-17 |
| AR092991A1 (es) | 2015-05-13 |
| ZA201503186B (en) | 2021-09-29 |
| HK1211255A1 (zh) | 2016-05-20 |
| MX359110B (es) | 2018-09-14 |
| SG11201502628SA (en) | 2015-05-28 |
| BR112015007870A2 (pt) | 2017-07-04 |
| JP2015536910A (ja) | 2015-12-24 |
| EP2906294A1 (en) | 2015-08-19 |
| ES2679372T3 (es) | 2018-08-24 |
| MX2015004428A (es) | 2015-06-24 |
| KR102157501B1 (ko) | 2020-09-18 |
| EP2906294B1 (en) | 2018-04-18 |
| CA2887628A1 (en) | 2014-04-17 |
| US20150297594A1 (en) | 2015-10-22 |
| AU2013329865B2 (en) | 2018-04-26 |
| IL238061B (en) | 2019-10-31 |
| CA2887628C (en) | 2020-09-08 |
| RU2015117550A (ru) | 2016-12-10 |
| RU2684407C2 (ru) | 2019-04-09 |
| IL238061A0 (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6240658B2 (ja) | 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体と他の抗腫瘍化合物との組み合わせ | |
| CN104703655A (zh) | 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 | |
| CN109715164A (zh) | 作为用于治疗脑癌之治疗剂的2-苯胺基嘧啶衍生物 | |
| JP6791855B2 (ja) | 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体とキナゾリン誘導体との組み合わせ | |
| CN106999493A (zh) | 具有抗癌活性的6‑氧代‑1,6‑二氢‑哒嗪衍生物与egfr抑制剂的组合 | |
| CN105848658A (zh) | 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与吉非替尼的组合 | |
| CN104768553A (zh) | 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物 | |
| CN105873591A (zh) | 用于治疗肾细胞癌（rcc）的6-氧代-1,6-二氢-哒嗪衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1211255 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150610 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1211255 Country of ref document: HK |